(Re)Formulating rotigotine: a potential molecule with unmet needs

Therapeutic DeliveryVol. 13, No. 9 Editorial(Re)Formulating rotigotine: a potential molecule with unmet needsParamita Saha, Deepak Chitkara & Murali Monohar PandeyParamita SahaIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, India, Deepak ChitkaraIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, India & Murali Monohar Pandey *Author for correspondence: Tel.: +91 1596 255 847; E-mail Address: pandeymm@pilani.bits-pilani.ac.inhttps://orcid.org/0000-0001-8988-046XIndustrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, 333031, IndiaPublished Online:25 Jan 2023https://doi.org/10.4155/tde-2022-0046AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: rotigotineParkinson's diseaseAlzheimer's diseasetraumatic brain injurynanoformulationsPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Wood M, Dubois V, Scheller D, Gillard M. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br. J. Pharmacol. 172(4), 1124–1135 (2015).Crossref, Medline, CAS, Google Scholar2. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn-Schmiedeberg's Arch. Pharmacol. 379(1), 73–86 (2009).Crossref, Medline, CAS, Google Scholar3. Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in parkinson's disease and restless legs syndrome. Drugs 75(5), 487–501 (2015). • Discusses the use of rotigotine (RTG) in Parkinson's disease (PD) and restless legs syndrome.Crossref, Medline, CAS, Google Scholar4. Li K, Zhang Y, Tian E, Liu Z, Wang T, Fu F. The effect of rotigotine extended-release microspheres alone or with celecoxib on the inflammatory pain. Front. Pharmacol. 11, 594387 (2020). •• This preclinical study provides information regarding use of RTG in PD-related pain.Crossref, Medline, CAS, Google Scholar5. Raeder V, Boura I, Leta V et al. Rotigotine transdermal patch for motor and non-motor parkinson's disease: a review of 12 years' clinical experience. CNS Drugs. 35, 215–231 (2021).Crossref, Medline, CAS, Google Scholar6. Bourgeois P, Frenette E. The status of rotigotine as a safe and effective alternative in the treatment of restless legs syndrome. Res. Rep. ransdermal Drug Deliv. 2, 1–8 (2013).Google Scholar7. Giacino JT, Whyte J, Bagiella E et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N. Engl. J.Med. 366(9), 819–826 (2012).Crossref, Medline, CAS, Google Scholar8. Plummer NR, Tam AWF, Mulvaney CA, Preston NJ, Laha SK. Dopamine agonists for traumatic brain injury. Cochrane Database Syst. Rev. 2018(6), CD013062 (2018).Google Scholar9. Gorgoraptis N, Mah YH, MacHner B et al. The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke. Brain: J. Neurolo. 135, 2478–2491 (2012). •• Provides information about potential of RTG in traumatic brain injury.Crossref, Medline, Google Scholar10. Nam E, Derrick JS, Lee S et al. Regulatory activities of dopamine and its derivatives toward metal-free and metal-induced amyloid-β aggregation, oxidative stress, and inflammation in Alzheimer's disease. ACS Chem. Neurosci. 9, 7 (2018).Crossref, Google Scholar11. Koch G, Di Lorenzo F, Bonnì S et al. Dopaminergic modulation of cortical plasticity in alzheimer's disease patients. Neuropsychopharmacology 39, 2654–2661 (2014). •• Provides information regarding potential of dopamine agonists in Alzheimer's disease.Crossref, Medline, CAS, Google Scholar12. Koch G, Motta C, Bonnì S et al. Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate Alzheimer disease: a randomized clinical trial. JAMA Netw. Open. 3(7), e2010372 (2020). •• A clinical study demonstrating effect of RTG in Alzheimer's.Crossref, Medline, Google Scholar13. Martorana A, Di Lorenzo F, Esposito Z et al. Dopamine D2-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients. Neuropharmacology 64, 108–113 (2013).Crossref, Medline, CAS, Google Scholar14. Bhattamisra SK, Shak AT, Xi LW et al. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of parkinson's disease. Int. J. Pharm. 579, 119148 (2020). • Demonstarting effect of nose to brain delivery of RTG in animal model of PD.Crossref, Medline, CAS, Google Scholar15. Bi CC, Wang AP, Chu YC et al. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for parkinson's disease treatment. Int. J. Nanomed. 11, 6547–6559 (2016). • This preclinical study showed effect of intranasal RTG-loaded nanoparticles in PD.Crossref, Medline, CAS, Google Scholar16. Wang F, Yang Z, Liu M et al. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: in vitro characterization and in vivo behavior study. Int. J. Pharm. 577, 119046 (2020).Crossref, Medline, CAS, Google Scholar17. Prajapati JB, Patel GC. Nose to brain delivery of rotigotine loaded solid lipid nanoparticles: quality by design based optimization and characterization. J. Drug Deliv. Sci. Technol. 63, 102377 (2021).Crossref, CAS, Google Scholar18. Wang A, Liu Y, Liang R et al. Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson's disease and its evolution study. Saudi. Pharm. J. 24(3), 363–370 (2016). • Demonstrating effcet of RTG-loaded implant in the treatment of PD.Crossref, Medline, CAS, Google Scholar19. Wang Z, Mu HJ, Zhang XM et al. Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies. Int. J. Nanomed 10, 633–644 (2015).Medline, Google Scholar20. Li X, Zhang R, Liang R et al. Preparation and characterization of sustained-release rotigotine film-forming gel. Int. J. Pharm. 460(1-2), 273–279 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited BySelf-Assembled Lecithin-Chitosan Nanoparticles Improved Rotigotine Nose-to-Brain Delivery and Brain Targeting Efficiency5 March 2023 | Pharmaceutics, Vol. 15, No. 3 Vol. 13, No. 9 Follow us on social media for the latest updates Metrics Downloaded 12 times History Received 15 August 2022 Accepted 30 November 2022 Published online 25 January 2023 Published in print September 2022 Information© 2023 Newlands PressKeywordsrotigotineParkinson's diseaseAlzheimer's diseasetraumatic brain injurynanoformulationsAuthor contributionsMM Pandey contributed to conception and design of the article. P Saha wrote the article. MM Pandey and D Chitkara reviewed and edited the article.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download